Advicenne receives MHRA approval to market Sibnayal in the UK for the treatment of distal renal tubular acidosis
Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.
